The 2023-2028 World Outlook for Transplants

The 2023-2028 World Outlook for Transplants

This study covers the world outlook for transplants across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of transplants as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 21st Century Medicine, Abbott Laboratories, AbbVie, Accord Healthcare, Allcells, Allergan, AlloSource, AmerisourceBergen Corporation, Apaxis Medical, Inc., Arthrex, Inc., Astellas Pharma, AveXis, Avita Medical, B. Braun Melsungen, Bard Peripheral Vascular, Baxter International, BioLife Solutions, BioTime, Boston Scientific Corporation, Bridge to Life, Bristol-Myers Squibb, Calon Cardio, CardiacAssist, Cardinal Health, Cayenne Medical, Chiesi Farmaceutici, Claris Lifesciences, Colibri Heart Valve, LLC., Coloplast, CONMED, ConvaTec, Cook Medical, CryoLife, Danaher Corporation, Dentsply International, DePuy Synthes, Dr. F. Köhler Chemie, Edwards Lifesciences Corporation, Envarsus XR, Exactech, F. Hoffmann-La Roche, Forticell Bioscience, Genzyme, Getinge Group, GlaxoSmithKline, Globus Medical, Harvard Apparatus Regenerative Technologies, HeartWare, Hill-Rom Holdings, Inc., Integra Lifescience, Johnson & Johnson, Junken Medical Company, Ltd., Karl Storz, Kiadis Pharma, Koninklijke Philips, LeMagitre Vascular, Inc., Lifeblood Medical, Lifeline Scientific, Lonza Group, McKesson Corporation, Medrotonic, Merck Millipore, Mylan Laboratories, Novartis, NuVasive, Olympus Optical Company, Optum, Organogenesis, Organovo, Orthofix Holdings, Penumbra, Pfizer, Preservation Solutions, Sanofi, Smith & Nephew, Specmed Medical, Stemcell Technologies, STERIS, Stratatech, Straumann Holding, Stryker, SynCardia Systems, Terumo Cardiovascular Group, Teva Pharmaceuticals, Thoratec, Tissue Regenix Group, TTK Healthcare, Veloxis Pharmaceuticals, Wright Medical Group, Zimmer Biomet, and Zoll Medical. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).